drugset / Trial / NCT03902522
PRO 140 in Treatment-Experienced HIV-1 Subjects
NaSingle-groupOpen-labelTreatment
Summary
The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.
Timeline
- Start
- 2018-06-25
- Primary completion
- 2020-05-18
- Completion
- 2020-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leronlimab | Monoclonal antibody | 350 mg | Subcutaneous |
| Subject | Leronlimab | Monoclonal antibody | 700 mg | Subcutaneous |